The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Survival outcomes in metastatic HR-positive, HER2-negative invasive ductal carcinoma compared to invasive lobular carcinoma and mixed ductal/lobular treated with endocrine therapy in combination with CDK4/6 inhibitors, mTOR inhibitor, or PI3K inhibitor.
 
Jason A Mouabbi
Consulting or Advisory Role - GE Healthcare
 
Akshara Singareeka Raghavendra
No Relationships to Disclose
 
Roland L. Bassett
No Relationships to Disclose
 
Amy Aida Hassan
Consulting or Advisory Role - AIM Specialty Health
 
Debu Tripathy
Consulting or Advisory Role - AstraZeneca; Genomic Health; GlaxoSmithKline; Novartis; OncoPep; Pfizer
Research Funding - Novartis (Inst); Pfizer (Inst); Polyphor (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis
 
Rachel M. Layman
Consulting or Advisory Role - Celcuity; Celcuity; Celcuity; GE Healthcare (I); Lilly; Novartis; Siemens (I)
Research Funding - Celcuity; Genentech (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Zentalis (Inst)
(OPTIONAL) Uncompensated Relationships - Lilly